Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3458
Gene Symbol: IFNG
IFNG
0.400 AlteredExpression disease BEFREE 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity. 22440312 2013
Entrez Id: 7124
Gene Symbol: TNF
TNF
0.400 AlteredExpression disease BEFREE Visceral leishmaniasis (VL) is associated with increased circulating levels of multiple pro-inflammatory cytokines and chemokines, including IL-12, IFNγ, and TNFα, and elevated expression of IFNγ mRNA in lesional tissue such as the spleen and bone marrow. 25275531 2014
Entrez Id: 3594
Gene Symbol: IL12RB1
IL12RB1
0.020 GeneticVariation disease BEFREE Visceral leishmaniasis in two patients with IL-12p40 and IL-12Rβ1 deficiencies. 27873456 2017
Entrez Id: 9688
Gene Symbol: NUP93
NUP93
0.010 GeneticVariation disease BEFREE Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response. 30001865 2019
Entrez Id: 3558
Gene Symbol: IL2
IL2
0.030 Biomarker disease BEFREE Visceral leishmaniasis is associated with a marked depression of T cell responses, which has been characterized by the absence of IL-2 and IFN-gamma production by lymphocytes on in vitro stimulation with Leishmania Ag. 8207220 1994
Entrez Id: 4153
Gene Symbol: MBL2
MBL2
0.050 Biomarker disease BEFREE Mannan-binding lectin enhances susceptibility to visceral leishmaniasis. 11447210 2001
Entrez Id: 28514
Gene Symbol: DLL1
DLL1
0.020 AlteredExpression disease BEFREE DLL1 expression was significantly (P = 2 × 10(-7)) reduced (mean fold change, 3.5 [SEM, 0.7]) in splenic aspirates from patients with VL, whereas other 6q27 genes showed higher levels (1.27 × 10(-6) < P < .01) than did the control spleen sample. 21742847 2011
Entrez Id: 3553
Gene Symbol: IL1B
IL1B
0.330 GeneticVariation disease BEFREE IL-1β (-511T/C) gene polymorphism not IL-1β (+3953T/C) and LT-α (+252A/G) gene variants confers susceptibility to visceral leishmaniasis. 22311026 2012
Entrez Id: 3162
Gene Symbol: HMOX1
HMOX1
0.320 Biomarker disease BEFREE Heme oxygenase-1 (HO-1) is a key enzyme triggered by cellular stress, and its role in VL has not been investigated. 22461696 2012
Entrez Id: 54106
Gene Symbol: TLR9
TLR9
0.030 AlteredExpression disease BEFREE TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis. 24670148 2014
Entrez Id: 7099
Gene Symbol: TLR4
TLR4
0.050 AlteredExpression disease BEFREE TLR4 and TLR9 were found to be highly expressed in patients with VL. 25982946 2015
Entrez Id: 3091
Gene Symbol: HIF1A
HIF1A
0.030 AlteredExpression disease BEFREE HIF-1α is a key regulator in potentiating suppressor activity and limiting the microbicidal capacity of MDSC-like cells during visceral leishmaniasis. 28892492 2017
Entrez Id: 6347
Gene Symbol: CCL2
CCL2
0.010 Biomarker disease BEFREE MCP-1 was also significantly elevated in all patients cured of visceral leishmaniasis (VL), unlike IL-2, indicating the specific memory response generated against <i>Leishmania</i>. 29033933 2017
Entrez Id: 3091
Gene Symbol: HIF1A
HIF1A
0.030 Biomarker disease BEFREE HIF-1α hampers dendritic cell function and Th1 generation during chronic visceral leishmaniasis. 29472618 2018
Entrez Id: 374569
Gene Symbol: ASPG
ASPG
0.010 Biomarker disease BEFREE Asparaginase, a pivotal enzyme of the aspartate metabolic pathway is present as two variants in Leishmania donovani, causative agent of visceral leishmaniasis (VL). 29551509 2018
Entrez Id: 51755
Gene Symbol: CDK12
CDK12
0.010 Biomarker disease BEFREE Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. 30046105 2018
Entrez Id: 57817
Gene Symbol: HAMP
HAMP
0.010 Biomarker disease BEFREE Hepcidin mediated iron homoeostasis as immune regulator in visceral leishmaniasis patients. 30402883 2019
Entrez Id: 3565
Gene Symbol: IL4
IL4
0.100 Biomarker disease BEFREE IL-4 Mediated Resistance of BALB/c Mice to Visceral Leishmaniasis Is Independent of IL-4Rα Signaling via T Cells. 31475014 2019
Entrez Id: 4843
Gene Symbol: NOS2
NOS2
0.020 AlteredExpression disease BEFREE A blood monocyte population with a gene signature comprising upregulated expression of TGM2, CTLRs, VDR, PKM, SOCS1, and CAMP1 and downregulated expression of NOS2 and HIF1A was observed in patients with VL but not in controls. 30053070 2018
Entrez Id: 3091
Gene Symbol: HIF1A
HIF1A
0.030 AlteredExpression disease BEFREE A blood monocyte population with a gene signature comprising upregulated expression of TGM2, CTLRs, VDR, PKM, SOCS1, and CAMP1 and downregulated expression of NOS2 and HIF1A was observed in patients with VL but not in controls. 30053070 2018
Entrez Id: 10404
Gene Symbol: CPQ
CPQ
0.010 Biomarker disease BEFREE A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. 22502587 2012
Entrez Id: 4843
Gene Symbol: NOS2
NOS2
0.020 AlteredExpression disease BEFREE According to RNase protection assay and immunohistochemistry, iNOS mRNA and protein were expressed at higher levels in bone marrow of patients with visceral leishmaniasis than in controls. 11441096 2001
Entrez Id: 965
Gene Symbol: CD58
CD58
0.020 AlteredExpression disease BEFREE Active cases of VL was observed with 2.91-fold increased mean florescence intensity (MFI) of LFA-3 expression on CD14(+) cells compared to healthy control (p = 0.0001). 23974052 2013
Entrez Id: 929
Gene Symbol: CD14
CD14
0.010 AlteredExpression disease BEFREE Active cases of VL was observed with 2.91-fold increased mean florescence intensity (MFI) of LFA-3 expression on CD14(+) cells compared to healthy control (p = 0.0001). 23974052 2013
Entrez Id: 9033
Gene Symbol: PKD2L1
PKD2L1
0.010 Biomarker disease BEFREE Active PV surveillance of targeted safety, effectiveness and key VL outcomes such us VL relapse, PKDL and HIV/VL co-infection should continue and PV data integrated to national and WHO PV databases. 28066878 2017